Panel seems to like Novartis drug

Share this content:

An FDA panel officially reviews an experimental Novartis psoriasis medication Monday, but Reuters notes that preview documents on the FDA's website indicate members consider secukinumab an approvable anti-inflammatory.

The FDA does not have to follow a panel's recommendations (as seen in the approval of the pain medication Zohydro) but often does.

A secukinumab approval would do more than merely give Novartis another product to market. Reuters notes that the drug is a member of a class of drugs known as IL-17 inhibitors, which have “shown unprecedented success in plaque-psoriasis, the most common form of the painful skin condition.”

Share this content:
Scroll down to see the next article